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DEVELOPMENT OF A MINIMALLY INVASIVE BONE MARROW HARVEST
DEVICE AND METHOD FOR THE RAPID EXTRACTION OF BONE MAR-
ROW FOR USE IN BONE MARROW TRANSPLANTATION AND STEM CELL
THERAPY
Kraft, D.L., Milroy, C., Negrin, R.S. Stanford University School of
Medicine, Division of Bone Marrow Transplantation, Stanford, CA.
The bone marrow contains a rich supply of hematopoetic, mes-
enchymal and other stem cell populations. Bone marrow and pe-
ripheral blood–derived hematopoetic stem cells are currently used
in  40,000 bone marrow and peripheral blood stem cell trans-
plants each year worldwide. Adult bone marrow–derived stem cells
may soon be used in various stem cell–mediated regenenerative
therapies, resulting in an increased need for a simpliﬁed, econom-
ical acquisition of bone marrow. Allogeneic marrow, or G-CSF
mobilized marrow, may prove to be superior to PBSC for several
transplantation indications, and thus improved harvest methods are
needed.
Current methods of acquiring stem cells are tedious and expen-
sive. Traditional methods for harvesting bone marrow from pa-
tients are crude and generally require 100 or more separate inser-
tions of a large trocar needle into the donor’s ileac crest. Serial
trocar insertions allow aspiration of a small volume of bone marrow
each time, eventually obtaining a volume of marrow containing an
adequate number of stem cells. Marrow donors usually require
general anesthesia, multiple staff, and often an overnight hospital
stay. Peripheral blood stem cell harvests, alsthough less invasive,
require the donor to undergo several days of expensive G-CSF
administration, followed by many hours of apheresis. Traditional
bone marrow harvests and peripheral blood transplants incur av-
erage charges approaching $15,000 per harvest.
We have developed a novel harvest device, the MarrowMiner, for
rapid, minimally invasive extraction of bone marrow. This device
requires only 1 or 2 separate bone marrow entry sites, because after
entry into ileac crest, the device can access most of the accessible
marrow space. We anticipate that the MarrowMiner device will
enable a single operator to harvest bone marrow in a short period
with only local anesthesia required in the outpatient setting, sig-
niﬁcantly facilitating convenient, on- demand stem cell collection
while signiﬁcantly reducing harvest costs. Collected marrow could
be used immediately or undergo stem cell enrichment and manip-
ulation for various current and potential future therapeudic indi-
cations. Results from the MarrowMiner device’s preclinical devel-
opment in miniature swine and human cadavers will be presented.
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IN VITRO UMBILICAL CORD BLOOD EXPANSION RESULTING IN
UNIQUE CD34BRIGHT CELL POPULATION THAT ENGRAFTS IN NOD/SCID
MICE
Xu, R., DeLuca, K., Porter, W., Garretson, L., Rowley, J.,
Liebmann-Vinson, A. BD Technologies, Research Triangle Parker, NC.
Umbilical cord blood (UCB) has gained recognition as a viable
alternative to bone marrow or mobilized peripheral blood for
hematopoietic stem cell transplantation and is being used for treat-
ment of mainly pediatric patients with various malignant or genetic
blood disorders. The limited number of cells contained in a single
cord blood unit remains the major bottleneck for broader applica-
tion of this treatment in adult patients. Extensive research is being
focused on strategies for overcoming this bottleneck. Expansion of
cells from a single cord blood unit or combining 2 cord blood units
for a single transplantation are the 2 most common strategies
currently in clinical evaluation.
Our research effort is focused on the expansion of umbilical cord
blood cells. At BD Technologies, we have developed a unique
higher-throughput technology platform that we have used success-
fully to identify a serum-free in vitro culture condition that sup-
ports expansion of UCB-derived cells. Expansion of UCB cells in
this condition results in a unique cell population, characterized by
a high level of glycoprotein CD34 expression. Characterization of
this expanded population using ﬂow cytometry, colony-forming
assays, and gene array analysis indicate that this expanded cell
population contains more primitive stem/progenitor cells than the
remainder of the CD34 population after expansion. When trans-
planted into sublethally irradiated NOD/SCID mice, these cells
were found to engraft in the bone marrow and to develop CD19
B-cell, CD33 myeloid, CD34 stem and progenitor, CD14
monocyte, and CD42 megakaryocyte lineages. Secondary trans-
plantation studies indicate the long-term engraftment potential of
the expanded cells.
In addition, when transplanted subcutaneously on porous poly-
mer carriers into NOD/SCID mice, the expanded cord blood cells
are found to initiate neovascularization within the carrier. Immu-
nohistochemistry revealed that human cord blood cells were in-
corporated into the new vasculature. We conclude that our culture
condition supports expansion of UCB cells that may have relevance
for therapeutic applications in humans.
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BONE MARROW–DERIVED MESENCHYMAL CELLS DELAY ALLOGENEIC
REJECTION
Kleiner, G.I., Gandia, C., Yu, H., Kadono, J., Coats, E., Defaria, W.,
Santiago, S., Ruiz, P., Tzakis, A. University of Miami School of
Medicine, Miami, FL.
Bone marrow–derived mesenchymal stem cells (BM-MSCs) have
been demonstrated to have immunosuppressive effects in mice and
humans. These ﬁndings suggest that they may be exploited in
organ transplantation settings. We investigated immunoregulatory
aspects of rat BM-MSCs. Bone marrow was extracted from 6- to
8-week-old DA rats and plated in 10% complete medium. Every 48
hours, nonadherent cells were discarded. The immunosuppressive
effects of these cells in an allogeneic mixed lymphocyte reaction
were investigated. MSCs dramatically suppressed MLR response
(99%) when added at a concentration of 105 MSCs. Suppression
was dose-dependent. In ConA cultures, MSC suppression of lym-
phoid cells was maximal at 105 cells. MSC suppression was not
MHC-restricted, because Lewis-derived MSCs also suppressed
MLR and ConA responses ( 90%). Immunoregulatory levels of
IL-6, IL-10, and TNF-	 were detected in supernatant of MSCs
(BioPlex assay). The ability of MSCs to suppress allogeneic skin
grafts was evaluated in an allogeneic rat model. Allogeneic skin
grafts survived for 7 days without immunosuppressive therapy. In
preliminary experiments, MSCs (derived from DA) were injected
either as a single dose (10  106/kg) or as multiple doses given
every 2 days (on days 0, 3, and 5). MSC injections, either a single
injection or multiple injections, delayed skin graft rejection (days
8–12 or 14). Multiple MSC injections (10  106/kg) suppressed
intestinal transplantation rejection in a rodent heterotopic intesti-
nal transplantation model as well. The results suggest that MSCs
may have clinical utility in transplantation settings.
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HUMAN MESENCHYMAL STEM CELLS AFFECT IGG PRODUCTION IN-
DUCED BY LIPOPOLYSACCHARIDE, CYTOMEGALOVIRUS AND VARI-
CELLA ZOSTER VIRUS IN HUMAN SPLEEN CELLS
Rasmusson, I.1, Sundberg, B.1, Le Blanc, K.1,2, Ringden, O.1,2 1Karo-
linska Institutet, Div of Clinical Immunology, Stockholm, Sweden; 2Cen-
ter for Allogeneic Stem Cell Transplantation, Karolinska University
Hospital Huddinge, Stockholm, Sweden.
Human mesenchymal stem cells (MSCs) suppress T-cell prolif-
eration and formation of cytotoxic T lymphocytes in vitro. In vivo,
MSCs prolong skin allograft survival and mitigate severe graft-
versus-host disease. The immunomodulatory properties of MSCs
have focused on T cells. We have examined the effects of MSCs on
human splenic B-cell IgG secretion. IgG response was analyzed
using the ELI-spot assays, after stimulating of human spleen cells
with lipopolysaccaride (LPS), cytomegalovirus (CMV), or varicella
zoster virus (VZV) antigens with or without 10% irradiated MSCs.
Unstimulated spleen cells gave 30  9 Spot-forming units (SFUs)/
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